tbuckley/cabot-search huggingface dataset:
AB0610 Correlation between traditional cardiovascular risk indexes and arterial stiffness in patients with generalised lupus erythematosus
Authors: M. Vázquez-Del Mercado, A. Llamas Garcia, A. Coldivar-Gabriel, E. Gomez-Bañuelos, D.A. Victoria-Rios, J.I. Lopez-Blasi, K.I. Arrona-Rios, F.D.J. Perez-Vazquez, G. Diaz-Rubio, F. Grover-Páez
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Cardiovascular disease (CVD) is the leading cause of late death in patients with systemic lupus erythematosus (SLE). SLE is related with up to 50 fold risk of CVD. SLE is recognised as an independent cardiovascular risk factor (CVR). However, traditional scales underestimates the CVR in SLE. <h3>Objectives</h3> Determine the correlation between traditional CVR scores (Framingham, systematic coronary risk evaluation (SCORE), arteriosclerotic cardiovascular disease (ASCVD) and arterial stiffness (AS) in an open population of SLE, assessing AS by pulse wave velocity (PWV), vascular damage through cardio-ankle vascular index (CAVI), ankle-brachial index (ABI), quality intima media thickness (qIMT) and SLE disease activity using the systemic lupus erythematosus disease activity index (SLEDAI) and systemic lupus international collaborating clinics (SLICC). <h3>Methods</h3> Patients with SLE of 18 years old and older, diagnosed according to SLICC 2012 criteria. Informed written consent. AS was determined by PWV, CAVI, ABI, and qIMT. Disease activity was recorded by SLEDAI and SLICC. Comparison between qualitative variables will be done through the X2 test or the Fisher exact test. For comparison of the quantitative variables with normal distribution Student's T and ANOVA tests were done. The correlation coefficient (r) of Pearson was calculated. Variables with a p≤0.2 value were included in a multiple linear regression model to evaluate the influence of the disease variables on CVR. SPSS v.22 software (IBM, inc) and the Graphpad V software were used. <h3>Results</h3> The total of SLE patient were 44 (100%), with a mean age of 34±12 years old. Thirty six women (82%). The mean evolution time was 6±5 years. Smoke was registered in 16% (7 cases). Systolic blood pressure 110±14, diastolic blood pressure 73±11 mmHg. Body mass index 28.4±9.1, total cholesterol 186±47, triglycerides 143±67, cHDL 42.9±5.1, cLDL 57±27 mg/dL. Erythrocyte sedimentation rate of 17±14 mm/hr, cReactive protein 7.1±4.8 mg/L. Anti.dsDNA antibodies were present in 47.7% of the cases.<sup>21</sup> Secondary antiphospholipid syndrome in 13.6%.<sup>6</sup> Mean SLEDAI 8 (range 0–32), mean SLICC 1 (range 0–6). C3 levels 83.6±21.4, C4 19.5±18.8 mg/dL. The most important correlations found were with qIMT and age 0.651 (&lt;0.001), BMI 0.513 (p 0.001), cRp 0.351 (0.033), cLDL 0.400 (0.01). Framingham score was able to predict CVR up to 44.8% the measurement of PWV, ASCVD in 30% and SCORE up to 22%. <h3>Conclusions</h3> Traditional scores (Framingham, SCORE, ASCVD) underestimate cardiovascular risk in patients with SLE. The most important finding is that qIMT was able to correlate more than age, to BMI and cLDL in SLE patients. <h3>Disclosure of Interest</h3> None declared
SAT0264 Does biological disease-modifying anti-rheumatic drug naÏve versus non-naÏve patients with inflammatory joint diseases have similar golimumab drug survival and efficacy? data from the prospective observational nor-dmard study
Authors: B. Michelsen, J. Sexton, T.K. Kvien
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Knowledge is limited regarding the impact of previously used biological disease modifying anti-rheumatic drugs (bDMARD) on golimumab drug survival and efficacy in inflammatory joint diseases (IJD). <h3>Objectives</h3> To explore golimumab drug survival and efficacy in bDMARD naïve vs. non-naïve IJD patients, as well as predictors of golimumab discontinuation. <h3>Methods</h3> From the observational prospective multicenter Norwegian-DMARD (NOR-DMARD) study rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (ax-SpA) patients starting golimumab were included. Drug survival was explored by Kaplan-Meier analyses with comparison of bDMARD naïve vs. non-naïve patients with log rank test, stratified by diagnosis. 3 month responses were compared with independent t-test, and with ANCOVA adjusted for age, gender, disease duration and baseline values of the respective composite scores. Univariable and multivariable Cox regression analyses including age, gender, disease duration, smoking, concomitant synthetic DMARDs (sDMARDs) and previous bDMARD use were performed to identify predictors of golimumab discontinuation. <h3>Results</h3> Mean (SD) age of the 163 RA, 267 PsA and 382 ax-SpA patients was 51.2 (14.1)/48.1 (11.7)/41.8 (11.1) years, disease duration 11.3 (10.0)/8.7 (9.0)/10.6 (11.2) years,%females 76.1/55.1/44.1%, respectively. Golimumab drug survival for bDMARD naïve vs. non-naïve patients was similar for all diagnoses (RA, p=0.15; PsA, p=0.23; ax-SpA p=0.71), with trend towards better drug survival in bDMARD naïve RA and PsA patients (figure). 4 year drug survival in bDMARD naïve/non-naïve patients were: RA, 54/48%; PsA, 47/43%; ax-SpA, 48/46%, respectively. Subgroup analyses of patients with and without concomitant sDMARDs showed similar findings. A trend was seen towards better 3 month responses in bDMARD naïve vs. non-naïve patients, with statistically significant better responses for DAS28 in PsA and BASDAI and ASDAS in ax-SpA (table 1). <h3>Conclusions</h3> Golimumab drug survival was similar in bDMARD naïve vs. non-naïve RA, PsA and ax-SpA patients. A trend was seen towards better responses for bDMARD naïve patients. Identified predictors for golimumab drug discontinuation was female gender and no concomitant sDMARDs in PsA and female gender in ax-SpA. <h3>Disclosure of Interest</h3> B. Michelsen Consultant for: Novartis, J. Sexton: None declared, T. Kvien Grant/research support from: AbbVie, BMS, MSD, Pfizer, Roche and UCB, Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Epirus, Hospira, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB
Partner Therapy in Sexually Transmitted Infections
Authors: Neil Keshvani, Ank Nijhawan, Arjun Gupta
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
OP0244 An asas-positive mri of the sacroiliac joints can also occur in healthy individuals, runners and women with postpartum back pain
Authors: J. de Winter, M. de Hooge, M. van de Sande, J. de Jong, L. van Hoeven, A. de Koning, I.J. Berg, R. Ramonda, D. Baeten, D. van der Heijde, A. Weel, R. Landewé
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Inflammation shown on MRI of the sacroiliac joint (MRI-SI) is prevalent in axSpA (±30%) but the specificity is not well known. <h3>Objectives</h3> To compare MRI of the sacroiliac joints (MRI-SI) of healthy, symptomless individuals and those with known mechanical strain acting upon SI joints to axial spondyloarthritis (axSpA) and chronic back pain (CBP) patients. <h3>Methods</h3> Three trained, calibrated and blinded readers randomly scored MRI-SI of 172 subjects: 47 healthy individuals without current/past back pain(;<sup><sup>1</sup></sup> 47 axSpA patients from the SPondyloArthritis Caught Early (SPACE) cohort (with a previously confirmed positive MRI-SI); 47 CBP controls (irrespective of MRI-SI results) from the SPACE cohort; 7 women with postpartum back pain; and 24 frequent runners. Readers scored according to the ASAS definition and SPARCC score. <h3>Results</h3> Of the 47 healthy volunteers, 11 (23.4%) had a positive MRI-SI, compared to 43 of 47 (91.5%) positive axSpA patients and 3 of 47 (6.4%) CBP patients. Of the runners, 3 of 24 (12.5%) and of the women with postpartum back pain 4 of 7 (57.1%) had a positive MRI-SI. Using a SPARCC cut-off of ≥2 for positivity, 12/47 and healthy volunteers (25.5%), 46/47 positive axSpA patients (97.9%), 5/47 CBP controls (10.6%), 4/24 runners (16.7%) and 4/7 women with postpartum back pain (57.1%) were positive. 'Deep' BME-lesions were not found in healthy volunteers, CBP patients and runners, but in 38 of 47 positive axSpA patients (80.9%) and in 1 of 7 women with postpartum back pain (14.3%). <h3>Conclusions</h3> A substantial proportion of healthy individuals without current/past back pain has a positive MRI-SI according to the ASAS definition. Deep (extensive) BME lesions are exclusively found in axSpA patients. <h3>Reference</h3> [1] van Hoeven L, Luime JJ, et al. Bone marrow edema and structural lesions in the sacroiliac joint in a large cohort of patients with axial spondyloarthritis, chronic low back pain and healthy controls. <i>ACR Annu Meet</i>2013;2889. <h3>Disclosure of Interest</h3> None declared
AB0235 Polymorphisms of hla-drb1 and tnf-308 g/a are associated with radiographic joint destruction in patients with very early rheumatoid arthritis
Authors: I. Guseva, A. Smirnov, N. Demidova, M. Krylov, A. Avdeeva, E. Samarkina, E. Luchikhina, E. Karateev, D. Abramov, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To clarify the association between HLA-DRB1 and TNFα (−308G&gt;A) genes polymorphism and joint destruction/further progression during 12 months of the follow-up period (FUP) in patients with early (&lt;6 months), active, predominantly ACPA and RF-positive RA treated according to "Treat to target" strategy. <h3>Methods</h3> The study included 85 patients with early RA and duration of symptoms&lt;6 months. RA diagnosis was established according to ACR/<sup>EULAR 2010</sup> criteria. All patients were initially assigned to subcutaneous methotrexate (MTX) with rapid dose escalation to 20–25 mg/week. Combination MTX+biological therapy, mainly adalimumab, was used when MTX was ineffective. Joint destruction was assessed by Sharp-Van der Heijde modification scoring method at baseline and after 12 months FUP. Real time polymerase chain reaction (PCR-RT) was used for TNFα gene polymorphism (−308G&gt;A) genotyping. Low resolution PCR-RT with subsequent sequence-based typing of *04 were performed to study HLA-DRB1 gene polymorphism. The HLA-DRB1*01, *04:01, *04:04, *04:05, *04:08, *10 alleles were categorised as SE+ (Shared Epitope) alleles. <h3>Results</h3> It was revealed that the number of erosions and joint space narrowings as well as the total Sharpe score were not associated with the presence and the dose of the SE alleles, either at baseline or after 12 months FUP. However, the progression of joint destruction, assessed as the change (Δ) in the number of erosions, joint space narrowings and the total score, was statistically significantly associated with HLA-DRB1*(SE) genotypes: the carriers of SE (SE+/SE+) double-dose had more advanced progression as compared to (SE+/SE-)/(SE-/SE-) carriers (p&lt;0,028, p&lt;0,019, p&lt;0,035, respectively). As for TNFα gene polymorphism, it was demonstrated that the number of narrowings and total Sharp score values were almost twice as high at baseline in GG genotype carriers as compared to GA genotype carriers (69,0<sup>49,5; 98,0</sup> and 37,0<sup>29,0; 63,0</sup> respectively, p&lt;0,005) and (72,0<sup>49,5; 98,5</sup> and 37,0,<sup>29,0; 63,0</sup> respectively, p&lt;0,004). Similar association was found after 12mo FUP, however, it should be mentioned that further progression of joint space narrowing and total Sharpe score was minimal (p&gt;0,05). <h3>Conclusions</h3> Our data suggest that HLA-DRB1 (SE+) gene polymorphism is associated with the progression of radiographic joint destruction at 12mo FUP in treated pts. Meanwhile TNFα (−308G&gt;A) polymorphism is associated with more pronounced joint destruction at baseline in terms of joint space narrowing and total Sharp score, but without further progression of joint destruction at 12mo in early and active RA pts managed according to "Treat to target" strategy. <h3>Disclosure of Interest</h3> None declared
Effect of Negative Pressure Wound Therapy vs Standard Wound Management on 12-Month Disability Among Adults With Severe Open Fracture of the Lower Limb
Authors: Matthew L. Costa, Juul Achten, Julie Bruce, Elizabeth Tutton, Stavros Petrou, Sarah E. Lamb, Nick R. Parsons
Journal: JAMA (2018)

<h3>Importance</h3> Open fractures of the lower limb occur when a broken bone penetrates the skin. There can be major complications from these fractures, which can be life-changing. <h3>Objectives</h3> To assess the disability, rate of deep infection, and quality of life in patients with severe open fracture of the lower limb treated with negative pressure wound therapy (NPWT) vs standard wound management after the first surgical debridement of the wound. <h3>Design, Setting, and Participants</h3> Multicenter randomized trial performed in the UK Major Trauma Network, recruiting 460 patients aged 16 years or older with a severe open fracture of the lower limb from July 2012 through December 2015. Final outcome data were collected through November 2016. Exclusions were presentation more than 72 hours after injury and inability to complete questionnaires. <h3>Interventions</h3> NPWT (n = 226) in which an open-cell solid foam or gauze was placed over the surface of the wound and connected to a suction pump, creating a partial vacuum over the dressing, vs standard dressings not involving application of negative pressure (n = 234). <h3>Main Outcomes and Measures</h3> Disability Rating Index score (range, 0 [no disability] to 100 [completely disabled]) at 12 months was the primary outcome measure, with a minimal clinically important difference of 8 points. Secondary outcomes were complications including deep infection and quality of life (score ranged from 1 [best possible] to −0.59 [worst possible]; minimal clinically important difference, 0.08) collected at 3, 6, 9, and 12 months. <h3>Results</h3> Among 460 patients who were randomized (mean age, 45.3 years; 74% men), 88% (374/427) of available study participants completed the trial. There were no statistically significant differences in the patients’ Disability Rating Index score at 12 months (mean score, 45.5 in the NPWT group vs 42.4 in the standard dressing group; mean difference, −3.9 [95% CI, −8.9 to 1.2];<i>P</i> = .13), in the number of deep surgical site infections (16 [7.1%] in the NPWT group vs 19 [8.1%] in the standard dressing group; difference, 1.0% [95% CI, −4.2% to 6.3%];<i>P</i> = .64), or in quality of life between groups (difference in EuroQol 5-dimensions questionnaire, 0.02 [95% CI, −0.05 to 0.08]; Short Form–12 Physical Component Score, 0.5 [95% CI, −3.1 to 4.1] and Mental Health Component Score, −0.4 [95% CI, −2.2 to 1.4]). <h3>Conclusions and Relevance</h3> Among patients with severe open fracture of the lower limb, use of NPWT compared with standard wound dressing did not improve self-rated disability at 12 months. The findings do not support this treatment for severe open fractures. <h3>Trial Registration</h3> isrctn.org Identifier:ISRCTN33756652
Influence of Lifestyle on Incident Cardiovascular Disease and Mortality in Patients With Diabetes Mellitus
Authors: Gang Liu, Yanping Li, Yang Hu, Geng Zong, Shanshan Li, Eric B. Rimm, Frank B. Hu, JoAnn E. Manson, Kathryn M. Rexrode, Hyun Joon Shin, Qi Sun
Journal: Journal of the American College of Cardiology (2018)
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC
Authors: David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi
Journal: Journal of Thoracic Oncology (2018)
Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial
Authors: Samir Jaber, Catherine Paugam, Emmanuel Futier, Jean-Yves Lefrant, Sigismond Lasocki, Thomas Lescot, Julien Pottecher, Alexandre Demoule, Martine Ferrandière, Karim Asehnoune, Jean Dellamonica, Lionel Velly, Paër-Sélim Abback, Audrey de Jong, Vincent Brunot, Fouad Belafia, Antoine Roquilly, Gérald Chanques, Laurent Muller, Jean-Michel Constantin, Helena Bertet, Kada Klouche, Nicolas Molinari, Boris Jung, Samir Jaber, Audrey de Jong, Fouad Belafia, Gérald Chanques, Marion Monnin, Jean-Marc Delay, Moussa Cissé, Marie Geniez, Matthieu Conseil, Bruno Souche, Catherine Paugam, Paër-Sélim Abback, Emmanuel Futier, Jean Michel Constantin, Jean-Yves Lefrant, Laurent Muller, Sigismond Lasocki, Thomas Lescot, Julien Pottecher, Eric Noll, Alexandre Demoule, Elise Morawiec, Martine Ferrandière, Karim Asehnoune, Antoine Roquilly, Jean Dellamonica, Alexandre Robert, Lionel Velly, Thibaut Triglia, Vincent Brunot, Nicolas Molinari, Malika Mechati, Jean-Michel Arnal, Jacques Durand-Gasselin, Didier Demoly, Sami Hraiech, Laurent Papazian, Vincent Gilles, Thomas Rimmelé, Béatrice Riu, Pierre Cougot, Olivier Fourcade, Philippe Seguin, Jonathan Charbit, Xavier Capdevila, Marc Leone, Laurent Zieleskiewicz, Carole Ichai, Jean Christophe Orban, Michael Darmon, Elie Azoulay, Virginie Lemiale, Lara Zafrani, Karim Debbat, Oliver Mimoz, Claude Guérin, Eric Kipnis
Journal: The Lancet (2018)
AB1300 Comorbidities in patients with rheumatic diseases in colombia
Authors: F.M. Cuervo, A. Santos, E.L. Saldarriaga, J.C. Rueda, I. Angarita, I. Peláez, E. Forero, J. Ramirez, C. Toro, J. Londono
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Patients with systemic autoimmune conditions often develop concomitant disease contributing to a higher mortality than in the general population. An early diagnosis and treatment is fundamental to improve the life expectancy of this population. <h3>Objectives</h3> The objective of this study was to describe the frequency of comorbidities in patients with rheumatic diseases. <h3>Methods</h3> Based on data from the population studied under the COPCORD strategy, in the prevalence of rheumatic disease in Colombia, the frequency of non-rheumatic diseases in patients with rheumatic diseases was described in 6 cities of Colombia (Bogotá, Medellín, Cali, Barranquilla, Bucaramanga and Cúcuta). <h3>Results</h3> From a total of 4020 individuals, 2274 rheumatic patients were identified. Sixty nine percent of the Colombian patients with rheumatic disease (n=1571) had some comorbidity. The most frequent was hypertension (HBP) in 20,95% (n=330), followed by migraine 19,11% (n=300) and venous insufficiency 17,69% (n=278). Seventeen percent had any mental disorders, of which, anxiety and depression were the most common (n=273). Other comorbidities like obesity (8,1%), diabetes (5,85%), heart disease (5,79%) and cerebrovascular disease (1,99%) were less common among rheumatic patients. The frequency of cancer was low 1.48% (n=23). <b>Abstract AB1300 – Figure 1</b> <h3>Conclusions</h3> Hypertension is the most common comorbidity in patients with rheumatic diseases in Colombia. Screening and diagnosis in early stages of HBP is important, since it is the main modifiable cardiovascular risk factor. The goals of pharmacological and non-pharmacological treatment are essential to reduce the risk of coronary heart disease, stroke and end-stage renal disease. Additionally, migraine is the second most frequent disease that affects the patient's quality of life. And venous insufficiency should be taken into account by primary care physicians in order to assure a complete health care assessment. <h3>Disclosure of Interest</h3> None declared
AB1400-HPR Muscle quality index in obese subjects with hip osteoarthritis
Authors: D.A Jerez, R. Machado, E. Cerda
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Obese older adults with hip osteoarthritis suffer a progressive loss of neuromuscular function affecting their activities of daily living. <h3>Objectives</h3> The objective of this study is to determine the behaviour of the muscular quality index in obese subjects with osteoarthritis and to compare the manifestations of strength and anthropometric variables with control subjects. <h3>Methods</h3> Thirty-two subjects (4 men and 28 women, 66.2±5.2 years of age, 159.2±7.5 cm, 71.5±11.7 kg) were evaluated. 14 subjects suffered osteoarthritis. Muscle circumference, limb length, body mass and sit and stand test were evaluated, in addition to the maximal voluntary isometric contraction in hip flexion and extension movements. <h3>Results</h3> The osteoarthritis group presented obesity (p=0.037). The muscle quality index of the osteoarthritis group correlated with the weight (p=0.776**), with maximum peak strength in flexion (p=0.552*) and average maximal strength (p=0.574*). In the control group the muscle quality index correlated with: weight (p=0.689**), muscle circumference (p=0.571*), maximum peak strength in extension (p=0.534*), average peak strength in extension (p=0,523*), average maximal strength in extension (p=0.509*) and maximum impulse in extension (p=0.508*). <h3>Conclusions</h3> The muscle quality index is a useful tool to measure muscle quality in the healthy population, but is not clear enough for obese subjects with osteoarthritis, so it is necessary to perform future studies to determine their behaviour. <h3>References</h3> [1] Fragala MS, Kenny AM, Kuchel GA. Muscle quality in aging: a multi-dimensional approach to muscle functioning with applications for treatment. Sports medicine (Auckland, NZ). 2015;45(5):641–58. Epub 2015/02/07. doi: 10.1007/s40279–015–0305-z. PubMed PMID: 25655372. [2] Fragala MS, Fukuda DH, Stout JR, Townsend JR, Emerson NS, Boone CH, et al. Muscle quality index improves with resistance exercise training in older adults. Experimental gerontology. 2014;53:1–6. Epub 2014/02/11. doi: 10.1016/j.exger.2014.01.027. PubMed PMID: 24508922. [3] Barbat-Artigas S, Rolland Y, Zamboni M, Aubertin-Leheudre M. How to assess functional status: a new muscle quality index. The journal of nutrition, health &amp; aging. 2012;16(1):67–77. Epub 2012/01/13. PubMed PMID: 22238004. [4] Takai Y, Ohta M, Akagi R, Kanehisa H, Kawakami Y, Fukunaga T. Sit-to-stand test to evaluate knee extensor muscle size and strength in the elderly: a novel approach. J Physiol Anthropol. 2009;28(3):123–8. PubMed PMID: 19483373. [5] van Lummel RC, Walgaard S, Maier AB, Ainsworth E, Beek PJ, van Dieën JH. The Instrumented Sit-to-Stand Test (iSTS) Has Greater Clinical Relevance than the Manually Recorded Sit-to-Stand Test in Older Adults. PLoS ONE. 2016;11(7):e0157968. doi: 10.1371/journal.pone.0157968. PubMed PMID: PMC4938439. <h3>Disclosure of Interest</h3> None declared
Stereotactic Body Radiation Therapy–Induced Abscopal Effect on Hepatocellular Carcinoma After Treatment for Lung Cancer: A Case Report
Authors: Fumiko Chino, Kimberly Ellen Pollis, Steve Choi, Joseph K Salama, Manisha Palta
Journal: Hepatology (2018)

Chino, Fumiko; Pollis, Kimberly Ellen; Choi, Steve; Salama, Joseph K; Palta, Manisha Author Information